Home Chevron right People Chevron right Professor John Staffurth
Professor John Staffurth
Teams and roles for John Staffurth
Publication
2025
Connor, M. J. et al., 2025. Combination cytoreductive surgery, radiotherapy, or ablation for De Novo metastatic prostate cancer: The IP2-ATLANTA Internal Pilot, Phase 2, randomised controlled trial.. European Urology Oncology (10.1016/j.euo.2025.05.010 )
Staffurth, J. et al. 2025. Real-world experience of 18F-PSMA-1007 PET-CT scanning for initial staging of high-risk non-metastatic prostate cancer: scan results and treatment decisions. Clinical Oncology 45 103900. (10.1016/j.clon.2025.103900 )Staffurth, J. N. et al. 2025. The impact of specialised gastroenterology services for pelvic radiation disease (PRD): Results from the prospective multi-centre EAGLE study. PLoS ONE 20 (1) e0303356. (10.1371/journal.pone.0303356 )Tree, A. C. et al., 2025. Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. The Lancet Oncology 26 (7), pp.936-947. (10.1016/S1470-2045(25)00205-0 )
2024
2023
Donovan, J. L. et al., 2023. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evidence 2 4. (10.1056/EVIDoa2300018 )
Fizazi, K. et al., 2023. Rucaparib or physician's choice in metastatic prostate cancer. New England Journal of Medicine 388 (8), pp.719-732. (10.1056/NEJMoa2214676 )
Gravestock, P. et al., 2023. Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. NIHR Open Research 2 49. (10.3310/nihropenres.13284.2 )
Hamdy, F. C. et al., 2023. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine 388 , pp.1547-1558. (10.1056/NEJMoa2214122 )
Parker, C. et al., 2023. Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response. JNCI Cancer Spectrum 7 (6) pkad077. (10.1093/jncics/pkad077 )
Ratnakumaran, R. et al., 2023. The association between acute and late genitourinary and gastrointestinal toxicities: an analysis of the PACE B study. Cancers 15 (4) 1288. (10.3390/cancers15041288 )
Syndikus, I. et al., 2023. 10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK/06/016).. 2023 ASCO Genitourinary Cancers Symposium San Francisco 16-18 February 2023. Vol. 41 .Vol. S6. American Society of Clinical Oncology. , pp.304-304. (10.1200/JCO.2023.41.6_suppl.304 )
2022
Lane, J. A. et al., 2022. Functional and quality of life outcomes of localised prostate cancer treatments (prostate testing for cancer and treatment [ProtecT] study). BJU International 130 (3), pp.370-380. (10.1111/bju.15739 )
Murray, J. et al., 2022. PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation. Clinical and Translational Radiation Oncology 37 , pp.130-136. (10.1016/j.ctro.2022.09.003 )
Smith, M. R. et al., 2022. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. The Lancet Oncology 23 (3), pp.362-373. (10.1016/S1470-2045(21)00757-9 )
Tree, A. C. et al., 2022. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology 23 (10)(10.1016/S1470-2045(22)00517-4 )
2021
Adamson, D. et al., 2021. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterology and Hepatology 6 (4), pp.292-303. (10.1016/S2468-1253(21)00004-2 )
Barrett, T. et al., 2021. Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting. BJU International 127 (3), pp.304-306. (10.1111/bju.15285 )
Connor, M. J. et al., 2021. Additional treatments to the local tumour for metastatic prostate cancer-assessment of novel treatment algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. BMJ Open 11 (2) e042953. (10.1136/bmjopen-2020-042953 )
Day, E. et al., 2021. Feasibility of comparative health research outcome of novel surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study. Trials 22 (1) 547. (10.1186/s13063-021-05509-w )
Jadon, R. et al., 2021. Dose-volume predictors for patient-reported late diarrhoea, faecal incontinence and urgency after pelvic radiotherapy. Clinical Oncology 33 (8), pp.536-545. (10.1016/j.clon.2021.03.011 )
Piazzese, C. et al. 2021. FIELDRT: an open-source platform for the assessment of target volume delineation in radiation therapy. British Journal of Radiology 94 (1126) 20210356. (10.1259/bjr.20210356 )Staffurth, J. N. et al. 2021. Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK/06/016). European Urology Oncology 4 (6), pp.980-992. (10.1016/j.euo.2021.07.005 )Sutton, E. et al., 2021. Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study. Cancer Causes and Control 32 (3), pp.261–269. (10.1007/s10552-020-01380-3 )
2020
Byrne, A. T. et al. 2020. Radiotherapy after esophageal cancer stenting (ROCS): A pragmatic randomized controlled trial evaluating the role of palliative radiotherapy in maintaining swallow.. Journal of Clinical Oncology 38 (15_sup) 4569. (10.1200/JCO.2020.38.15_suppl.4569 )Farnell, D. et al. 2020. The ALERT-B questionnaire: a screening tool for the detection of gastroenterological late effects after radiotherapy for prostate cancer. Clinical and Translational Radiation Oncology 21 , pp.98-103. (10.1016/j.ctro.2020.02.002 )Jacinta, A. and Staffurth, J. 2020. Hormonal therapy for cancer. Medicine 48 (2), pp.103-107. (10.1016/j.mpmed.2019.11.007 )
Macnair, A. et al., 2020. The Trigger project: the challenge of introducing electronic patient-reported outcome measures into a radiotherapy service. Clinical Oncology 32 (2), pp.e76-e79. (10.1016/j.clon.2019.09.044 )
Murray, J. et al., 2020. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Radiotherapy and Oncology 142 , pp.62-71. (10.1016/j.radonc.2019.10.017 )
Murray, J. et al., 2020. Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial. European Urology 21 , pp.77-84. (10.1016/j.ctro.2019.12.006 )
Neal, D. E. et al., 2020. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. European Urology 77 (3), pp.320-330. (10.1016/j.eururo.2019.10.030 )
Reddy, D. et al., 2020. Comparative healthcare research outcomes of novel surgery in prostate cancer (IP4-CHRONOS): a prospective, multi-centre therapeutic phase II parallel randomised control trial. Contemporary Clinical Trials 93 105999. (10.1016/j.cct.2020.105999 )
Turnham, D. J. et al. 2020. The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells 9 (11) 2342. (10.3390/cells9112342 )
2019
Clark, E. et al., 2019. Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open 9 e034708. (10.1136/bmjopen-2019-034708 )
Cox, S. et al. 2019. Impact of deviations in target volume delineation - Time for a new RTQA approach?. Radiotherapy and Oncology 137 , pp.1-8. (10.1016/j.radonc.2019.04.012 )Dearnaley, D. et al., 2019. Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL). International Journal of Radiation Oncology - Biology - Physics 103 (3), pp.605-617. (10.1016/j.ijrobp.2018.10.003 )
Evans, E. et al., 2019. EP-1666 ARENA: Improving training in target volume delineation for radiotherapy. Radiotherapy and Oncology 133 (S1), pp.S896-S897. (10.1016/S0167-8140(19)32086-9 )
Foley, K. G. et al. 2019. External validation of a prognostic model incorporating quantitative PET image features in esophageal cancer. Radiotherapy and Oncology 133 , pp.205-212. (10.1016/j.radonc.2018.10.033 )Hargreaves, S. et al. 2019. Interim 18F-FDG positron emission tomography/computed tomography during chemoradiotherapy in the management of cancer patients: a response [Letter]. Clinical Oncology 31 (9), pp.669-670. (10.1016/j.clon.2019.05.005 )Jadon, R. et al. 2019. A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy. Radiation Oncology 14 (1), pp.-. 57. (10.1186/s13014-019-1262-8 )Nelson, A. , Mann, M. and Staffurth, J. 2019. Methods of assessing late radiotherapy effects on bowel function. Current Opinion in Supportive and Palliative Care 13 (2), pp.134-141. (10.1097/SPC.0000000000000422 )Parkinson, C. et al. 2019. Machine-learned target volume delineation of 18F-FDG PET images after one cycle of induction chemotherapy. Physica Medica, European Journal of Medical Physics 61 , pp.85-93. (10.1016/j.ejmp.2019.04.020 )Payne, H. et al., 2019. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice. International Journal of Clinical Practice 73 (9), pp.1-6. e13292. (10.1111/ijcp.13292 )
Piazzese, C. et al. 2019. PO-0964 Stability and prognostic significance of CT radiomic features from oesophageal cancer patients. Radiotherapy and Oncology 133 (S1), pp.S524-S525. (10.1016/S0167-8140(19)31384-2 )Richards, R. et al., 2019. The preferences of patients with cancer regarding an app to help them to meet their illness-related information needs: a qualitative interview study. JMIR mHealth and uHealth 7 (7) e14187. (10.2196/14187 )
Wheeler, P. et al., 2019. OC-0183 Multi-institutional evaluation of a Pareto navigation guided automated planning solution. Radiotherapy and Oncology 133 (S1), pp.S92. (10.1016/S0167-8140(19)30603-6 )
Wheeler, P. A. et al., 2019. Utilisation of Pareto navigation techniques to calibrate a fully automated radiotherapy treatment planning solution. Physics and Imaging in Radiation Oncology 10 , pp.41-48. (10.1016/j.phro.2019.04.005 )
Wheeler, P. A. et al., 2019. Evaluating the application of Pareto navigation guided automated radiotherapy treatment planning to prostate cancer. Radiotherapy and Oncology 141 , pp.220-226. (10.1016/j.radonc.2019.08.001 )
Whybra, P. et al. 2019. A novel normalisation technique for voxel size dependent radiomic features in oesophageal cancer [Abstract]. Radiotherapy and Oncology 133 , pp.S523-S524. (10.1016/S0167-8140(19)31383-0 )Whybra, P. et al. 2019. PO-0963 A novel normalisation technique for voxel size dependent radiomic features in oesophageal cancer. Radiotherapy and Oncology 133 (S1), pp.S523-S524. (10.1016/S0167-8140(19)31383-0 )Whybra, P. et al. 2019. Assessing radiomic feature robustness to interpolation in 18F-FDG PET imaging. Scientific Reports 9 (1) 9649. (10.1038/s41598-019-46030-0 )
2018
Donovan, J. L. et al., 2018. A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology 96 , pp.35-46. (10.1016/j.jclinepi.2017.12.019 )
Parkinson, C. et al. 2018. Dependency of patient risk stratification on PET target volume definition in Oesophageal cancer. Radiotherapy and Oncology 127 (S1), pp.S503-S504. (10.1016/S0167-8140(18)31241-6 )Parkinson, C. et al. 2018. Target volume delineation of PET post one cycle of induction chemotherapy in oropharyngeal cancer. Radiotherapy and Oncology 127 (S1), pp.S634-S635. EP-1126. (10.1016/S0167-8140(18)31436-1 )Parkinson, C. et al. 2018. Dependency of patient risk stratification on PET target volume definition in oesophageal cancer. ESTRO Barcelona, Spain 20-24 April 2018. Parkinson, C. et al. 2018. Evaluation of prognostic models developed using standardised image features from different PET automated segmentation methods. EJNMMI Research 8 29. (10.1186/s13550-018-0379-3 )Parkinson, C. et al. 2018. Target volume delineation of FDG PET images post one cycle of induction chemotherapy in oropharyngeal cancer using advanced automated segmentation methods. ESTRO 37 Barcelona 20-24 April 2018. Parkinson, C. et al. 2018. ATLAAS - Investigation into the incorporation of morphological data on automated segmentation. EANM Congress 2018: European Association of Nuclear Medicine. Dusseldorf, Germany 12-18 October 2018. Piazzese, C. et al. 2018. Evaluation of 2D and 3D radiomics features extracted from CT images of oesophageal cancer patients. Radiotherapy and Oncology 127 , pp.S1180-S1181. (10.1016/S0167-8140(18)32450-2 )Richards, R. et al. 2018. Use of mobile devices to help cancer patients meet their information needs in non-inpatient settings: systematic review. JMIR mHealth and uHealth 6 (12) e10026. (10.2196/10026 )Whybra, P. et al. 2018. Effect of interpolation on 3D texture analysis of PET imaging in oesophageal cancer. Radiotherapy and Oncology 127 (S1), pp.S1164-S1165. (10.1016/S0167-8140(18)32426-5 )Woods, B. S. et al., 2018. Addition of Docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. European Urology Oncology 1 (6), pp.449-458. (10.1016/j.euo.2018.06.004 )
2017
2016
Abraham, J. and Staffurth, J. N. 2016. Hormonal therapy for cancer. Medicine 44 (1), pp.30-33. (10.1016/j.mpmed.2015.10.014 )
Andronis, L. et al., 2016. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International 119 (4), pp.522-529. (10.1111/bju.13549 )
Carrington, R. et al., 2016. The influence of radiotherapy treatment method on dose distribution and its relation to patient outcome in the SCOPE 1 oesophageal cancer trial using Type B algorithms. Radiation Oncology (London, England) 11 19. (10.1186/s13014-016-0594-x )
Carrington, R. et al. 2016. The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial. Radiation Oncology 11 19. (10.1186/s13014-016-0594-x )Dearnaley, D. et al., 2016. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology 17 (8), pp.1047-1060. (10.1016/S1470-2045(16)30102-4 )
Fokas, E. et al., 2016. P-222 Analysis of tumour contours and radiotherapy planning of 'on-trial' patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of 'on-trial' radiotherapy?. Annals of Oncology 27 (sup. 2), pp.ii64.3-ii65. (10.1093/annonc/mdw199.214 )
Fokas, E. et al., 2016. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: analysis of the on-trial cases for the SCALOP trial. Radiotherapy and Oncology 120 (2), pp.212-216. (10.1016/j.radonc.2016.07.002 )
Gnanapragasam, V. et al., 2016. Clinical management and research priorities for high-risk prostate cancer in the UK: Meeting report of a multidisciplinary panel in conjunction with the NCRI Prostate Cancer Clinical Studies Localised Subgroup. Journal of Clinical Urology 9 (6), pp.369-379. (10.1177/2051415816651362 )
Gwynne, S. et al., 2016. Prospective review of radiotherapy trials through implementation of standardised multi-centre workflow and IT infrastructure. British Journal of Radiology 89 20160020. (10.1259/bjr.20160020 )
James, N. et al., 2016. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment 20 (53)(10.3310/hta20530 )
James, N. D. et al., 2016. Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both. JAMA Oncology 2 (4), pp.493-499. (10.1001/jamaoncol.2015.5570 )
Johnston, T. J. et al., 2016. Mortality among men with advanced prostate cancer excluded from the ProtecT trial. European Urology 71 (3), pp.381-388. (10.1016/j.eururo.2016.09.040 )
Sharma, R. A. et al., 2016. Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology 13 , pp.627-642. (10.1038/nrclinonc.2016.79 )
Tanguay, J. S. et al., 2016. High risk of neutropenia for hormone-naive prostate cancer patients receiving STAMPEDE-style upfront Docetaxel chemotherapy in usual clinical practice. Clinical Oncology 28 (9), pp.611-611. (10.1016/j.clon.2016.03.006 )
Taylor, S. et al. 2016. The three-item ALERT-B questionnaire provides a validated screening tool to detect chronic gastrointestinal symptoms after pelvic radiotherapy in cancer survivors. Clinical Oncology 28 (10), pp.e139-e147. (10.1016/j.clon.2016.06.004 )Taylor, S. et al. 2016. Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project. British Medical Journal Open 6 (10) e011773. (10.1136/bmjopen-2016-011773 )Taylor, S. E. et al., 2016. Late effects of pelvic radiation treatment (EAGLE study) [Abstract]. Journal of Clinical Oncology 34 (3), pp.159. (10.1200/jco.2016.34.3_suppl.159 )
2015
Carrington, R. et al., 2015. A radiobiological investigation of dose escalation in lower oesophageal tumours with a focus on gastric toxicity. Medical Physics 42 (6), pp.3346-3347. (10.1118/1.4924430 )
Carrington, R. et al. 2015. The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation. Radiation Oncology 10 236. (10.1186/s13014-015-0537-y )Fokas, E. et al., 2015. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. Radiotherapy and Oncology 117 (3), pp.432-437. (10.1016/j.radonc.2015.08.026 )
Harris, V. A. et al., 2015. Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy. International Journal of Radiation Oncology*Biology*Physics 92 (4), pp.874-883. (10.1016/j.ijrobp.2015.03.021 )
Hurt, C. N. et al. 2015. Health-related quality of life in SCALOP, a randomized Phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 93 (4), pp.810-818. Hurt, C. N. et al. 2015. Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. International Journal of Radiation Oncology*Biology*Physics 93 (4), pp.810-818. (10.1016/j.ijrobp.2015.08.026 )Rees, J. et al., 2015. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. British Journal of Cancer 113 (4), pp.603-610. (10.1038/bjc.2015.258 )
Salimu, J. et al. 2015. Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells—A Key Role for Heat-Shock Protein 70 and Receptor CD91. Cancer Immunology Research 3 (6), pp.678-688. (10.1158/2326-6066.CIR-14-0079 )
2014
Adamson, D. et al., 2014. Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial. Trials 15 402. (10.1186/1745-6215-15-402 )
Jadon, R. et al., 2014. A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer. Clinical Oncology 26 (4), pp.185-196. (10.1016/j.clon.2013.11.031 )
Spary, L. K. et al. 2014. Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation. The Journal of Immunology 192 (7), pp.3101-3110. (10.4049/jimmunol.1302736 )Voskoboynik, M. et al., 2014. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert Review of Anticancer Therapy 14 (11), pp.1253-1256. (10.1586/14737140.2014.971112 )
2013
Crosby, T. et al., 2013. SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab. American Journal of Clinical Oncology 31 (Supp 4) LBA3. (10.1200/jco.2013.31.4_suppl.lba3 )
Crosby, T. D. L. et al. 2013. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. The Lancet Oncology 14 (7), pp.627-637. (10.1016/S1470-2045(13)70136-0 )Mukherjee, S. et al., 2013. SCALOP: Results of a randomized phase II study of induction chemotherapy followed by genicitabine (G) or capecitabine (Cap) based chentoradialion (CRT) in locally advanced pancreatic cancer (LANPC).. American Journal of Clinical Oncology 31 (Supp 4)
Mukherjee, S. et al., 2013. Comparison of investigator-delineated GTV in chemoradiotherapy (CRT) for locally advanced nonmetastatic pancreatic cancer (LANPC): Analysis of the pretrial test case for the SCALOP trial. Journal of Clinical Oncology 31 (4) 230.
Mukherjee, S. et al., 2013. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. The Lancet Oncology 14 (4), pp.317-326. (10.1016/S1470-2045(13)70021-4 )
Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87 (2), pp.S306. (10.1016/j.ijrobp.2013.06.804 )Thomas, B. M. et al., 2013. Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. Medical Oncology 30 (4) 719. (10.1007/s12032-013-0719-0 )
2012
Burnet, N. G. et al., 2012. Methodological considerations in the evaluation of radiotherapy technologies [Editorial]. Clinical Oncology 24 (10), pp.707-709. (10.1016/j.clon.2012.06.003 )
Dearnaley, D. et al., 2012. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHiP randomised controlled trial. The Lancet Oncology 13 (1), pp.43-54. (10.1016/S1470-2045(11)70293-5 )
Fizazi, K. et al., 2012. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 13 (10), pp.983-992. (10.1016/S1470-2045(12)70379-0 )
Gwynne, S. et al. 2012. Imaging for target volume delineation in rectal cancer radiotherapy - A systematic review. Clinical Oncology 24 (1), pp.52-63. (10.1016/j.clon.2011.10.001 )Gwynne, S. H. et al. 2012. Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case. International Journal of Radiation Oncology*Biology*Physics 84 (4), pp.1037-1042. (10.1016/j.ijrobp.2012.01.094 )Gwynne, S. H. et al. 2012. Image-guided radiotherapy for rectal cancer - A systematic review. Clinical Oncology 24 (4), pp.250-260. (10.1016/j.clon.2011.07.012 )Hummel, S. R. et al., 2012. A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. Clinical Oncology 24 (10), pp.e159-e167. (10.1016/j.clon.2012.09.003 )
Mackay, R. I. et al., 2012. Radiotherapy physics research in the UK: challenges and proposed solutions. British Journal of Radiology 85 (1018), pp.1354-1362. (10.1259/bjr/61530686 )
Mayles, W. P. M. et al., 2012. Progress with intensity-modulated radiotherapy implementation in the UK. Clinical Oncology 24 (8), pp.543-544. (10.1016/j.clon.2012.06.005 )
Nilsson, S. et al., 2012. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. European Journal of Cancer 48 (5), pp.678-686. (10.1016/j.ejca.2011.12.023 )
Spezi, E. et al. 2012. Patient-specific three-dimensional concomitant dose from cone beam computed tomography exposure in image-guided radiotherapy. International Journal of Radiation Oncology*Biology*Physics 83 (1), pp.419-426. (10.1016/j.ijrobp.2011.06.1972 )
2011
2010
Button, M. R. and Staffurth, J. N. 2010. Clinical Application of Image-guided Radiotherapy in Bladder and Prostate Cancer. Clinical Oncology 22 (8), pp.698-706. (10.1016/j.clon.2010.06.020 )Guerrero Urbano, T. et al., 2010. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clinical Oncology 22 (3), pp.236-244. (10.1016/j.clon.2010.01.005 )
Mackay, R. I. et al., 2010. UK guidelines for the safe delivery of intensity-modulated radiotherapy.. Clinical Oncology 22 (8), pp.629-635.
Mukherjee, S. et al., 2010. A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. American Journal of Clinical Oncology 28
Routsis, D. et al., 2010. Education and training for intensity-modulated radiotherapy in the UK. Clinical Oncology 22 (8), pp.675-680. (10.1016/j.clon.2010.06.012 )
Staffurth, J. N. 2010. A review of the clinical evidence for intensity-modulated radiotherapy. Clinical Oncology 22 (8), pp.643-657. (10.1016/j.clon.2010.06.013 )Tabi, Z. et al. 2010. Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. The Journal of Immunology 185 (2), pp.1330-1339. (10.4049/jimmunol.1000488 )Welton, J. L. et al. 2010. Proteomics analysis of bladder cancer exosomes. Molecular & Cellular Proteomics 9 (6), pp.1324-1338. (10.1074/mcp.M000063-MCP201 )Williams, M. V. et al., 2010. The implementation of intensity-modulated radiotherapy in the UK. Clinical Oncology 22 (8), pp.623-628. (10.1016/j.clon.2010.06.015 )
2009
Gwynne, S. et al. 2009. Respiratory movement of upper abdominal organs and its effect on radiotherapy planning in pancreatic cancer1. Clinical Oncology 21 (9), pp.713-719. (10.1016/j.clon.2009.07.015 )Jones, C. E. et al., 2009. The development and introduction of a written post-radiotherapy information leaflet for prostate cancer patients [Abstract]. Clinical Oncology 21 (3), pp.270. (10.1016/j.clon.2009.01.001 )
Mitchell, P. J. et al. 2009. Can urinary exosomes act as treatment response markers in prostate cancer?. Journal Of Translational Medicine 7 (4), pp.n/a. (10.1186/1479-5876-7-4 )Nixon, L. S. et al. 2009. Implementation of a QA RT substudy for SCOPE 1; Preliminary results for test cases [Abstract]. Clinical Oncology 21 (3), pp.255-255. (10.1016/j.clon.2009.01.001, )Shelley, M. D. et al., 2009. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treatment Reviews 35 (7), pp.540-546. (10.1016/j.ctrv.2009.05.001 )
Shelley, M. D. et al., 2009. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treatment Reviews 35 (1), pp.9-17. (10.1016/j.ctrv.2008.08.002 )
Sutcliffe, P. et al., 2009. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technology Assessment 13 (5), pp.1-242. (10.3310/hta13050 )
Wills, L. et al., 2009. The effect of planning algorithms in oesophageal radiotherapy in the context of the SCOPE 1 trial. Radiotherapy and Oncology 93 (3), pp.462-467. (10.1016/j.radonc.2009.08.036 )
2008
Abraham, J. and Staffurth, J. N. 2008. Hormonal therapy for cancer. Medicine 36 (1), pp.29-32. (10.1016/j.mpmed.2007.10.010 )
Abraham, J. and Staffurth, J. N. 2008. Hormones in cancer. Practical clinical oncology . Cambridge: Cambridge University Press. , pp.23-38.
Barber, J. and Staffurth, J. N. 2008. Prostate. Practical clinical oncology . Cambridge: Cambridge University Press. , pp.231-239. Barber, J. and Staffurth, J. N. 2008. Testis. Practical clinical oncology . Cambridge: Cambridge University Press. , pp.240-251. Hudson, E. et al., 2008. Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies. Clinical Oncology 20 (5), pp.353-357. (10.1016/j.clon.2008.02.008 )
Staffurth, J. N. and Mason, M. D. 2008. Radiotherapy for early prostate cancer. International handbook of prostate cancer. 3rd ed . Hampshire: Euromed Communications Limited. , pp.161-182.
2007
Articles
Abraham, J. and Staffurth, J. N. 2008. Hormonal therapy for cancer. Medicine 36 (1), pp.29-32. (10.1016/j.mpmed.2007.10.010 )
Abraham, J. and Staffurth, J. N. 2016. Hormonal therapy for cancer. Medicine 44 (1), pp.30-33. (10.1016/j.mpmed.2015.10.014 )
Adamson, D. et al., 2014. Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial. Trials 15 402. (10.1186/1745-6215-15-402 )
Adamson, D. et al., 2021. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterology and Hepatology 6 (4), pp.292-303. (10.1016/S2468-1253(21)00004-2 )
Andronis, L. et al., 2016. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International 119 (4), pp.522-529. (10.1111/bju.13549 )
Barrett, T. et al., 2021. Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting. BJU International 127 (3), pp.304-306. (10.1111/bju.15285 )
Burnet, N. G. et al., 2012. Methodological considerations in the evaluation of radiotherapy technologies [Editorial]. Clinical Oncology 24 (10), pp.707-709. (10.1016/j.clon.2012.06.003 )
Button, M. R. and Staffurth, J. N. 2010. Clinical Application of Image-guided Radiotherapy in Bladder and Prostate Cancer. Clinical Oncology 22 (8), pp.698-706. (10.1016/j.clon.2010.06.020 )Byrne, A. T. et al. 2020. Radiotherapy after esophageal cancer stenting (ROCS): A pragmatic randomized controlled trial evaluating the role of palliative radiotherapy in maintaining swallow.. Journal of Clinical Oncology 38 (15_sup) 4569. (10.1200/JCO.2020.38.15_suppl.4569 )Carrington, R. et al., 2016. The influence of radiotherapy treatment method on dose distribution and its relation to patient outcome in the SCOPE 1 oesophageal cancer trial using Type B algorithms. Radiation Oncology (London, England) 11 19. (10.1186/s13014-016-0594-x )
Carrington, R. et al., 2015. A radiobiological investigation of dose escalation in lower oesophageal tumours with a focus on gastric toxicity. Medical Physics 42 (6), pp.3346-3347. (10.1118/1.4924430 )
Carrington, R. et al. 2016. The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial. Radiation Oncology 11 19. (10.1186/s13014-016-0594-x )Carrington, R. et al. 2015. The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation. Radiation Oncology 10 236. (10.1186/s13014-015-0537-y )Clark, E. et al., 2019. Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open 9 e034708. (10.1136/bmjopen-2019-034708 )
Connor, M. J. et al., 2025. Combination cytoreductive surgery, radiotherapy, or ablation for De Novo metastatic prostate cancer: The IP2-ATLANTA Internal Pilot, Phase 2, randomised controlled trial.. European Urology Oncology (10.1016/j.euo.2025.05.010 )
Connor, M. J. et al., 2021. Additional treatments to the local tumour for metastatic prostate cancer-assessment of novel treatment algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. BMJ Open 11 (2) e042953. (10.1136/bmjopen-2020-042953 )
Cox, S. et al. 2019. Impact of deviations in target volume delineation - Time for a new RTQA approach?. Radiotherapy and Oncology 137 , pp.1-8. (10.1016/j.radonc.2019.04.012 )Crosby, T. et al., 2013. SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab. American Journal of Clinical Oncology 31 (Supp 4) LBA3. (10.1200/jco.2013.31.4_suppl.lba3 )
Crosby, T. D. L. et al. 2013. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. The Lancet Oncology 14 (7), pp.627-637. (10.1016/S1470-2045(13)70136-0 )Crosby, T. et al., 2017. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/? cetuximab in oesophageal cancer. British Journal of Cancer 116 (6), pp.709-716. (10.1038/bjc.2017.21 )
Day, E. et al., 2021. Feasibility of comparative health research outcome of novel surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study. Trials 22 (1) 547. (10.1186/s13063-021-05509-w )
de Bono, J. S. et al., 2011. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364 (21), pp.1995-2005. (10.1056/NEJMoa1014618 )
Dearnaley, D. et al., 2019. Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL). International Journal of Radiation Oncology - Biology - Physics 103 (3), pp.605-617. (10.1016/j.ijrobp.2018.10.003 )
Dearnaley, D. et al., 2016. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology 17 (8), pp.1047-1060. (10.1016/S1470-2045(16)30102-4 )
Dearnaley, D. et al., 2012. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHiP randomised controlled trial. The Lancet Oncology 13 (1), pp.43-54. (10.1016/S1470-2045(11)70293-5 )
Donovan, J. L. et al., 2023. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evidence 2 4. (10.1056/EVIDoa2300018 )
Donovan, J. L. et al., 2018. A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology 96 , pp.35-46. (10.1016/j.jclinepi.2017.12.019 )
Evans, E. et al., 2019. EP-1666 ARENA: Improving training in target volume delineation for radiotherapy. Radiotherapy and Oncology 133 (S1), pp.S896-S897. (10.1016/S0167-8140(19)32086-9 )
Farnell, D. et al. 2020. The ALERT-B questionnaire: a screening tool for the detection of gastroenterological late effects after radiotherapy for prostate cancer. Clinical and Translational Radiation Oncology 21 , pp.98-103. (10.1016/j.ctro.2020.02.002 )Fizazi, K. et al., 2023. Rucaparib or physician's choice in metastatic prostate cancer. New England Journal of Medicine 388 (8), pp.719-732. (10.1056/NEJMoa2214676 )
Fizazi, K. et al., 2012. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 13 (10), pp.983-992. (10.1016/S1470-2045(12)70379-0 )
Fokas, E. et al., 2016. P-222 Analysis of tumour contours and radiotherapy planning of 'on-trial' patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of 'on-trial' radiotherapy?. Annals of Oncology 27 (sup. 2), pp.ii64.3-ii65. (10.1093/annonc/mdw199.214 )
Fokas, E. et al., 2015. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. Radiotherapy and Oncology 117 (3), pp.432-437. (10.1016/j.radonc.2015.08.026 )
Fokas, E. et al., 2016. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: analysis of the on-trial cases for the SCALOP trial. Radiotherapy and Oncology 120 (2), pp.212-216. (10.1016/j.radonc.2016.07.002 )
Foley, K. G. et al. 2019. External validation of a prognostic model incorporating quantitative PET image features in esophageal cancer. Radiotherapy and Oncology 133 , pp.205-212. (10.1016/j.radonc.2018.10.033 )Gnanapragasam, V. et al., 2016. Clinical management and research priorities for high-risk prostate cancer in the UK: Meeting report of a multidisciplinary panel in conjunction with the NCRI Prostate Cancer Clinical Studies Localised Subgroup. Journal of Clinical Urology 9 (6), pp.369-379. (10.1177/2051415816651362 )
Gravestock, P. et al., 2023. Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. NIHR Open Research 2 49. (10.3310/nihropenres.13284.2 )
Guerrero Urbano, T. et al., 2010. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clinical Oncology 22 (3), pp.236-244. (10.1016/j.clon.2010.01.005 )
Gwynne, S. et al. 2012. Imaging for target volume delineation in rectal cancer radiotherapy - A systematic review. Clinical Oncology 24 (1), pp.52-63. (10.1016/j.clon.2011.10.001 )Gwynne, S. et al., 2011. Inter-observer variation in outlining of pre-trial test case in the SCOPE1 trial: A United Kingdom definitive chemoradiotherapy trial for esophageal cancer. International Journal of Radiation Oncology - Biology - Physics 81 (2), pp.S67-S68. (10.1016/j.ijrobp.2011.06.135 )
Gwynne, S. et al., 2011. Imaging for rectal cancer radiotherapy - a systematic review. Clinical Oncology 23 (3), pp.S37-S37.
Gwynne, S. et al., 2016. Prospective review of radiotherapy trials through implementation of standardised multi-centre workflow and IT infrastructure. British Journal of Radiology 89 20160020. (10.1259/bjr.20160020 )
Gwynne, S. et al. 2009. Respiratory movement of upper abdominal organs and its effect on radiotherapy planning in pancreatic cancer1. Clinical Oncology 21 (9), pp.713-719. (10.1016/j.clon.2009.07.015 )Gwynne, S. H. et al. 2012. Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case. International Journal of Radiation Oncology*Biology*Physics 84 (4), pp.1037-1042. (10.1016/j.ijrobp.2012.01.094 )Gwynne, S. H. et al. 2012. Image-guided radiotherapy for rectal cancer - A systematic review. Clinical Oncology 24 (4), pp.250-260. (10.1016/j.clon.2011.07.012 )Hamdy, F. C. et al., 2023. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine 388 , pp.1547-1558. (10.1056/NEJMoa2214122 )
Hargreaves, S. et al. 2019. Interim 18F-FDG positron emission tomography/computed tomography during chemoradiotherapy in the management of cancer patients: a response [Letter]. Clinical Oncology 31 (9), pp.669-670. (10.1016/j.clon.2019.05.005 )Harnden, P. et al., 2007. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. The Lancet Oncology 8 (5), pp.411-419. (10.1016/S1470-2045(07)70136-5 )
Harris, V. A. et al., 2015. Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy. International Journal of Radiation Oncology*Biology*Physics 92 (4), pp.874-883. (10.1016/j.ijrobp.2015.03.021 )
Hudson, E. et al., 2008. Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies. Clinical Oncology 20 (5), pp.353-357. (10.1016/j.clon.2008.02.008 )
Hummel, S. R. et al., 2012. A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. Clinical Oncology 24 (10), pp.e159-e167. (10.1016/j.clon.2012.09.003 )
Hurt, C. N. et al. 2017. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. British Journal of Cancer 116 (10), pp.1264-1270. (10.1038/bjc.2017.95 )Hurt, C. N. et al. 2015. Health-related quality of life in SCALOP, a randomized Phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 93 (4), pp.810-818. Hurt, C. N. et al. 2015. Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. International Journal of Radiation Oncology*Biology*Physics 93 (4), pp.810-818. (10.1016/j.ijrobp.2015.08.026 )Jacinta, A. and Staffurth, J. 2020. Hormonal therapy for cancer. Medicine 48 (2), pp.103-107. (10.1016/j.mpmed.2019.11.007 )
Jadon, R. et al., 2021. Dose-volume predictors for patient-reported late diarrhoea, faecal incontinence and urgency after pelvic radiotherapy. Clinical Oncology 33 (8), pp.536-545. (10.1016/j.clon.2021.03.011 )
Jadon, R. et al., 2014. A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer. Clinical Oncology 26 (4), pp.185-196. (10.1016/j.clon.2013.11.031 )
Jadon, R. et al. 2019. A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy. Radiation Oncology 14 (1), pp.-. 57. (10.1186/s13014-019-1262-8 )James, N. et al., 2016. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment 20 (53)(10.3310/hta20530 )
James, N. D. et al., 2016. Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both. JAMA Oncology 2 (4), pp.493-499. (10.1001/jamaoncol.2015.5570 )
Johnston, T. J. et al., 2016. Mortality among men with advanced prostate cancer excluded from the ProtecT trial. European Urology 71 (3), pp.381-388. (10.1016/j.eururo.2016.09.040 )
Jones, C. E. et al., 2009. The development and introduction of a written post-radiotherapy information leaflet for prostate cancer patients [Abstract]. Clinical Oncology 21 (3), pp.270. (10.1016/j.clon.2009.01.001 )
Lane, J. A. et al., 2022. Functional and quality of life outcomes of localised prostate cancer treatments (prostate testing for cancer and treatment [ProtecT] study). BJU International 130 (3), pp.370-380. (10.1111/bju.15739 )
Mackay, R. I. et al., 2012. Radiotherapy physics research in the UK: challenges and proposed solutions. British Journal of Radiology 85 (1018), pp.1354-1362. (10.1259/bjr/61530686 )
Mackay, R. I. et al., 2010. UK guidelines for the safe delivery of intensity-modulated radiotherapy.. Clinical Oncology 22 (8), pp.629-635.
Macnair, A. et al., 2020. The Trigger project: the challenge of introducing electronic patient-reported outcome measures into a radiotherapy service. Clinical Oncology 32 (2), pp.e76-e79. (10.1016/j.clon.2019.09.044 )
Mayles, W. P. M. et al., 2012. Progress with intensity-modulated radiotherapy implementation in the UK. Clinical Oncology 24 (8), pp.543-544. (10.1016/j.clon.2012.06.005 )
Mitchell, P. J. et al. 2009. Can urinary exosomes act as treatment response markers in prostate cancer?. Journal Of Translational Medicine 7 (4), pp.n/a. (10.1186/1479-5876-7-4 )Mukherjee, S. et al., 2010. A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. American Journal of Clinical Oncology 28
Mukherjee, S. et al., 2013. SCALOP: Results of a randomized phase II study of induction chemotherapy followed by genicitabine (G) or capecitabine (Cap) based chentoradialion (CRT) in locally advanced pancreatic cancer (LANPC).. American Journal of Clinical Oncology 31 (Supp 4)
Mukherjee, S. et al., 2013. Comparison of investigator-delineated GTV in chemoradiotherapy (CRT) for locally advanced nonmetastatic pancreatic cancer (LANPC): Analysis of the pretrial test case for the SCALOP trial. Journal of Clinical Oncology 31 (4) 230.
Mukherjee, S. et al., 2013. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. The Lancet Oncology 14 (4), pp.317-326. (10.1016/S1470-2045(13)70021-4 )
Murray, J. et al., 2022. PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation. Clinical and Translational Radiation Oncology 37 , pp.130-136. (10.1016/j.ctro.2022.09.003 )
Murray, J. et al., 2020. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Radiotherapy and Oncology 142 , pp.62-71. (10.1016/j.radonc.2019.10.017 )
Murray, J. et al., 2020. Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial. European Urology 21 , pp.77-84. (10.1016/j.ctro.2019.12.006 )
Neal, D. E. et al., 2020. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. European Urology 77 (3), pp.320-330. (10.1016/j.eururo.2019.10.030 )
Nelson, A. , Mann, M. and Staffurth, J. 2019. Methods of assessing late radiotherapy effects on bowel function. Current Opinion in Supportive and Palliative Care 13 (2), pp.134-141. (10.1097/SPC.0000000000000422 )Nilsson, S. et al., 2012. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. European Journal of Cancer 48 (5), pp.678-686. (10.1016/j.ejca.2011.12.023 )
Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87 (2), pp.S306. (10.1016/j.ijrobp.2013.06.804 )Nixon, L. S. et al. 2009. Implementation of a QA RT substudy for SCOPE 1; Preliminary results for test cases [Abstract]. Clinical Oncology 21 (3), pp.255-255. (10.1016/j.clon.2009.01.001, )Parker, C. et al., 2023. Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response. JNCI Cancer Spectrum 7 (6) pkad077. (10.1093/jncics/pkad077 )
Parkinson, C. et al. 2018. Dependency of patient risk stratification on PET target volume definition in Oesophageal cancer. Radiotherapy and Oncology 127 (S1), pp.S503-S504. (10.1016/S0167-8140(18)31241-6 )Parkinson, C. et al. 2018. Target volume delineation of PET post one cycle of induction chemotherapy in oropharyngeal cancer. Radiotherapy and Oncology 127 (S1), pp.S634-S635. EP-1126. (10.1016/S0167-8140(18)31436-1 )Parkinson, C. et al. 2019. Machine-learned target volume delineation of 18F-FDG PET images after one cycle of induction chemotherapy. Physica Medica, European Journal of Medical Physics 61 , pp.85-93. (10.1016/j.ejmp.2019.04.020 )Parkinson, C. et al. 2018. Evaluation of prognostic models developed using standardised image features from different PET automated segmentation methods. EJNMMI Research 8 29. (10.1186/s13550-018-0379-3 )Payne, H. et al., 2019. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice. International Journal of Clinical Practice 73 (9), pp.1-6. e13292. (10.1111/ijcp.13292 )
Piazzese, C. et al. 2018. Evaluation of 2D and 3D radiomics features extracted from CT images of oesophageal cancer patients. Radiotherapy and Oncology 127 , pp.S1180-S1181. (10.1016/S0167-8140(18)32450-2 )Piazzese, C. et al. 2021. FIELDRT: an open-source platform for the assessment of target volume delineation in radiation therapy. British Journal of Radiology 94 (1126) 20210356. (10.1259/bjr.20210356 )Piazzese, C. et al. 2019. PO-0964 Stability and prognostic significance of CT radiomic features from oesophageal cancer patients. Radiotherapy and Oncology 133 (S1), pp.S524-S525. (10.1016/S0167-8140(19)31384-2 )Ratnakumaran, R. et al., 2023. The association between acute and late genitourinary and gastrointestinal toxicities: an analysis of the PACE B study. Cancers 15 (4) 1288. (10.3390/cancers15041288 )
Reddy, D. et al., 2020. Comparative healthcare research outcomes of novel surgery in prostate cancer (IP4-CHRONOS): a prospective, multi-centre therapeutic phase II parallel randomised control trial. Contemporary Clinical Trials 93 105999. (10.1016/j.cct.2020.105999 )
Rees, J. et al., 2015. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. British Journal of Cancer 113 (4), pp.603-610. (10.1038/bjc.2015.258 )
Richards, R. et al., 2019. The preferences of patients with cancer regarding an app to help them to meet their illness-related information needs: a qualitative interview study. JMIR mHealth and uHealth 7 (7) e14187. (10.2196/14187 )
Richards, R. et al. 2018. Use of mobile devices to help cancer patients meet their information needs in non-inpatient settings: systematic review. JMIR mHealth and uHealth 6 (12) e10026. (10.2196/10026 )Routsis, D. et al., 2010. Education and training for intensity-modulated radiotherapy in the UK. Clinical Oncology 22 (8), pp.675-680. (10.1016/j.clon.2010.06.012 )
Salimu, J. et al. 2015. Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells—A Key Role for Heat-Shock Protein 70 and Receptor CD91. Cancer Immunology Research 3 (6), pp.678-688. (10.1158/2326-6066.CIR-14-0079 )Sharma, R. A. et al., 2016. Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology 13 , pp.627-642. (10.1038/nrclinonc.2016.79 )
Shelley, M. D. et al., 2009. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treatment Reviews 35 (7), pp.540-546. (10.1016/j.ctrv.2009.05.001 )
Shelley, M. D. et al., 2009. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treatment Reviews 35 (1), pp.9-17. (10.1016/j.ctrv.2008.08.002 )
Smith, M. R. et al., 2022. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. The Lancet Oncology 23 (3), pp.362-373. (10.1016/S1470-2045(21)00757-9 )
Spary, L. K. et al. 2014. Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation. The Journal of Immunology 192 (7), pp.3101-3110. (10.4049/jimmunol.1302736 )Spezi, E. et al. 2012. Patient-specific three-dimensional concomitant dose from cone beam computed tomography exposure in image-guided radiotherapy. International Journal of Radiation Oncology*Biology*Physics 83 (1), pp.419-426. (10.1016/j.ijrobp.2011.06.1972 )Staffurth, J. et al. 2025. Real-world experience of 18F-PSMA-1007 PET-CT scanning for initial staging of high-risk non-metastatic prostate cancer: scan results and treatment decisions. Clinical Oncology 45 103900. (10.1016/j.clon.2025.103900 )Staffurth, J. N. et al. 2021. Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK/06/016). European Urology Oncology 4 (6), pp.980-992. (10.1016/j.euo.2021.07.005 )Staffurth, J. N. et al. 2025. The impact of specialised gastroenterology services for pelvic radiation disease (PRD): Results from the prospective multi-centre EAGLE study. PLoS ONE 20 (1) e0303356. (10.1371/journal.pone.0303356 )Staffurth, J. N. 2010. A review of the clinical evidence for intensity-modulated radiotherapy. Clinical Oncology 22 (8), pp.643-657. (10.1016/j.clon.2010.06.013 )Sutcliffe, P. et al., 2009. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technology Assessment 13 (5), pp.1-242. (10.3310/hta13050 )
Sutton, E. et al., 2021. Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study. Cancer Causes and Control 32 (3), pp.261–269. (10.1007/s10552-020-01380-3 )
Tabi, Z. et al. 2010. Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. The Journal of Immunology 185 (2), pp.1330-1339. (10.4049/jimmunol.1000488 )Tanguay, J. S. et al., 2016. High risk of neutropenia for hormone-naive prostate cancer patients receiving STAMPEDE-style upfront Docetaxel chemotherapy in usual clinical practice. Clinical Oncology 28 (9), pp.611-611. (10.1016/j.clon.2016.03.006 )
Taylor, S. et al. 2016. The three-item ALERT-B questionnaire provides a validated screening tool to detect chronic gastrointestinal symptoms after pelvic radiotherapy in cancer survivors. Clinical Oncology 28 (10), pp.e139-e147. (10.1016/j.clon.2016.06.004 )Taylor, S. et al. 2016. Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project. British Medical Journal Open 6 (10) e011773. (10.1136/bmjopen-2016-011773 )Taylor, S. E. et al., 2016. Late effects of pelvic radiation treatment (EAGLE study) [Abstract]. Journal of Clinical Oncology 34 (3), pp.159. (10.1200/jco.2016.34.3_suppl.159 )
Thomas, B. M. et al., 2013. Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. Medical Oncology 30 (4) 719. (10.1007/s12032-013-0719-0 )
Tree, A. C. et al., 2025. Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. The Lancet Oncology 26 (7), pp.936-947. (10.1016/S1470-2045(25)00205-0 )
Tree, A. C. et al., 2022. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology 23 (10)(10.1016/S1470-2045(22)00517-4 )
Turnham, D. J. et al. 2020. The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells 9 (11) 2342. (10.3390/cells9112342 )Turnham, D. J. et al. 2024. Development and characterisation of a new patient-derived Xenograft model of AR-negative metastatic asctration-resistant prostate cancer. Cells 13 (8) 673. (10.3390/cells13080673 )van As, N. et al., 2024. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. New England Journal of Medicine 391 (15), pp.1413-1425. (10.1056/NEJMoa2403365 )
Voskoboynik, M. et al., 2014. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert Review of Anticancer Therapy 14 (11), pp.1253-1256. (10.1586/14737140.2014.971112 )
Welton, J. L. et al. 2010. Proteomics analysis of bladder cancer exosomes. Molecular & Cellular Proteomics 9 (6), pp.1324-1338. (10.1074/mcp.M000063-MCP201 )Wheeler, P. et al., 2019. OC-0183 Multi-institutional evaluation of a Pareto navigation guided automated planning solution. Radiotherapy and Oncology 133 (S1), pp.S92. (10.1016/S0167-8140(19)30603-6 )
Wheeler, P. A. et al., 2019. Utilisation of Pareto navigation techniques to calibrate a fully automated radiotherapy treatment planning solution. Physics and Imaging in Radiation Oncology 10 , pp.41-48. (10.1016/j.phro.2019.04.005 )
Wheeler, P. A. et al., 2024. Multi-institutional evaluation of a Pareto navigation guided automated radiotherapy planning solution for prostate cancer. Radiation Oncology 19 45. (10.1186/s13014-024-02404-x )
Wheeler, P. A. et al., 2019. Evaluating the application of Pareto navigation guided automated radiotherapy treatment planning to prostate cancer. Radiotherapy and Oncology 141 , pp.220-226. (10.1016/j.radonc.2019.08.001 )
Whybra, P. et al. 2019. A novel normalisation technique for voxel size dependent radiomic features in oesophageal cancer [Abstract]. Radiotherapy and Oncology 133 , pp.S523-S524. (10.1016/S0167-8140(19)31383-0 )Whybra, P. et al. 2019. PO-0963 A novel normalisation technique for voxel size dependent radiomic features in oesophageal cancer. Radiotherapy and Oncology 133 (S1), pp.S523-S524. (10.1016/S0167-8140(19)31383-0 )Whybra, P. et al. 2018. Effect of interpolation on 3D texture analysis of PET imaging in oesophageal cancer. Radiotherapy and Oncology 127 (S1), pp.S1164-S1165. (10.1016/S0167-8140(18)32426-5 )Whybra, P. et al. 2019. Assessing radiomic feature robustness to interpolation in 18F-FDG PET imaging. Scientific Reports 9 (1) 9649. (10.1038/s41598-019-46030-0 )Williams, M. V. et al., 2010. The implementation of intensity-modulated radiotherapy in the UK. Clinical Oncology 22 (8), pp.623-628. (10.1016/j.clon.2010.06.015 )
Wills, L. et al., 2017. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy. Radiation Oncology 12 (1) 179. (10.1186/s13014-017-0916-7 )
Wills, L. et al., 2009. The effect of planning algorithms in oesophageal radiotherapy in the context of the SCOPE 1 trial. Radiotherapy and Oncology 93 (3), pp.462-467. (10.1016/j.radonc.2009.08.036 )
Woods, B. S. et al., 2018. Addition of Docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. European Urology Oncology 1 (6), pp.449-458. (10.1016/j.euo.2018.06.004 )
Book sections
Abraham, J. and Staffurth, J. N. 2008. Hormones in cancer. Practical clinical oncology . Cambridge: Cambridge University Press. , pp.23-38.
Barber, J. and Staffurth, J. N. 2008. Prostate. Practical clinical oncology . Cambridge: Cambridge University Press. , pp.231-239. Barber, J. and Staffurth, J. N. 2008. Testis. Practical clinical oncology . Cambridge: Cambridge University Press. , pp.240-251. Staffurth, J. N. and Mason, M. D. 2008. Radiotherapy for early prostate cancer. International handbook of prostate cancer. 3rd ed . Hampshire: Euromed Communications Limited. , pp.161-182.
Conferences
![John Staffurth](https://profiles-cardiff.imgix.net/attachments/2608?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")